Physiomics Technology in support of Eli Lilly Oncology Program

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has signed an agreement with Eli Lilly and Company (‘Lilly’) (NYSE: LLY), the global pharmaceutical company, to provide in silico simulations of cancer cellular processes in support of Lilly’s cancer drug discovery research.

Physiomics will deploy its modelling expertise in biological systems, in close collaboration with Lilly’s global PK/PD/TS (pharmacokinetics,  pharmacodynamics and trial simulation) department and oncology discovery group. The research programme will initially be focused on drugs targeting the cell cycle (the natural process of controlling cell proliferation) – a process that is frequently disrupted in cancers.

Dr Christophe Chassagnole, COO of Physiomics, said:

‘We are delighted that Lilly has chosen Physiomics as a partner in the systems biology field applied to our special focus area of oncology. This is a very positive step forward for Physiomics as a further major pharma company joins our growing list of partners at a time when interest in application of systems biology to pharma R&D is increasing very rapidly.’

Contact Details:

Physiomics plc: Dr Christophe Chassagnole, phone +44 (0)1865 784982
E-mail: cchassagnole@physiomics-plc.com

Grant Thornton Corporate Finance: Philip Secrett and Colin Aaronson, phone +44 (0) 20
7383 5100

 

})(jQuery)